AIHW logo
METEOR logo
Our sites
AIHW GEN Aged Care Data Aboriginal and Torres Strait Islander
Health Performance Framework
Indigenous Mental Health and
Suicide Prevention Clearinghouse
Australian Mesothelioma Registry Housing data Regional Insights for Indigenous Communities
Contact FAQs
  • Find metadata
    • Find metadata
    • Getting started
    • Data set specifications
    • Indicator sets
    • Data quality statements
    • Data dictionary archives
  • Metadata management
    • Metadata management
    • Data standards
    • Registration authorities
    • Registration statuses
  • How to use METEOR
    • How to use METEOR
    • First steps
    • Using My Page
    • Downloading and printing
    • FAQs
    • About METEOR
  • Learn about metadata
    • Learn about metadata
    • Metadata explained
    • How to create metadata
    • Metadata development resources

Person—cholesterol level (measured), total millimoles per litre N[N].N

Identifying and definitional attributes

Metadata item type:Help on this termData Element
Short name:Help on this termCholesterol—total (measured)
METEOR identifier:Help on this term359245
Registration status:Help on this term
  • Health, Standard 01/10/2008
Definition:Help on this term

A person's total cholesterol (TC), measured in millimoles per litre.

Data Element Concept:Person—cholesterol level

Value domain attributes

Representational attributes

Representation class:Help on this termTotal
Data type:Help on this termNumber
Format:Help on this termN[N].N
Maximum character length:Help on this term3
Supplementary values:Help on this term
ValueMeaning
99.9Not stated/inadequately described.
Unit of measure:Help on this termMillimole per litre (mmol/L)

Data element attributes

Collection and usage attributes

Guide for use:Help on this term

Measurement in mmol/L to 1 decimal place.

Record the absolute result of the total cholesterol measurement. When reporting, record whether or not the measurement of Cholesterol-total - measured was performed in a fasting specimen.

Collection methods:Help on this term

When reporting, record absolute result of the most recent Cholesterol-total - measured in the last 12 months to the nearest 0.1 mmol/L.

Measurement of lipid levels should be carried out by laboratories, or practices, which have been accredited to perform these tests by the National Association of Testing Authorities.

  • To be collected as a single venous blood sample, preferably following a 12-hour fast where only water and medications have been consumed.
  • Prolonged tourniquet use can artefactually increase levels by up to 20%.
Comments:Help on this term

In settings where the monitoring of a person's health is ongoing and where a measure can change over time (such as general practice), the Service contact—service contact date, DDMMYYYY should be recorded.

High blood cholesterol is a key factor in heart, stroke and vascular disease, especially coronary heart disease.

Poor nutrition can be a contributing factor to heart, stroke and vascular disease as a population's level of saturated fat intake is the prime determinant of its level of blood cholesterol.

Large clinical trials have shown that people at highest risk of cardiovascular events (e.g. pre-existing ischaemic heart disease) will derive the greatest benefit from lipid lowering drugs. Recent trials have suggested that there should be no cholesterol level threshold for the initiation of treatment in this group of patients. In October 2006, the PBS criteria for lipid-lowering drugs was expanded to include all patients identified as high-risk (based on PBS criteria) regardless of their cholesterol level.

Source and reference attributes

Submitting organisation:Help on this term

Cardiovascular Data Working Group

Origin:Help on this term

National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand, Lipid Management Guidelines - 2001, MJA 2001; 175: S57-S88

National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand, Position Statement on Lipid Management - 2005, Heart Lung and Circulation 2005; 14: 275-291.

National Health Priority Areas Report: Cardiovascular Health 1998. AIHW Cat. No. PHE 9. HEALTH and AIHW, Canberra.

The Royal College of Pathologists of Australasia web based Manual of Use and Interpretation of Pathology Tests. Version 4.0.

Relational attributes

Related metadata references:Help on this term
Supersedes Person—cholesterol level (measured), total millimoles per litre N[N].N
  • Health, Superseded 01/10/2008
Implementation in Data Set Specifications:Help on this term
All attributes +

Acute coronary syndrome (clinical) DSSHealth, Superseded 01/09/2012

Acute coronary syndrome (clinical) DSSHealth, Superseded 02/05/2013

Acute coronary syndrome (clinical) NBPDS Health, Recorded 15/05/2017

Acute coronary syndrome (clinical) NBPDS 2013-Health, Standard 02/05/2013

DSS specific attributes +

Implementation start date: 01/07/2013


Cardiovascular disease (clinical) DSSHealth, Superseded 01/09/2012

DSS specific attributes +

DSS specific information:

Scientific studies have shown a continuous relationship between lipid levels and coronary heart disease and overwhelming evidence that lipid lowering interventions reduce coronary heart disease progression, morbidity and mortality. Studies show a positive relationship between an individual's total blood cholesterol level and risk of coronary heart disease as well as death (Kannel & Gordon 1970; Pocock et al. 1989).

Many studies have demonstrated the significance of blood cholesterol components as risk factors for heart, stroke and vascular disease.

Several generalisations can be made from these cholesterol lowering trials:

  • that the results of the intervention trials are consistent with the prospective population studies in which (excluding possible regression dilution bias) a 1.0 mmol/L reduction in plasma total cholesterol translates into an approximate 20% reduction in the risk of future coronary events.
  • It should be emphasised, however, that this conclusion does not necessarily apply beyond the range of cholesterol levels which have been tested in these studies.
  • That the benefits of cholesterol lowering are apparent in people with and without coronary artery disease.

There is high level evidence that in patients with existing coronary heart disease, lipid intervention therapy reduces the risk of subsequent stroke


Cardiovascular disease (clinical) NBPDSHealth, Superseded 17/10/2018

DSS specific attributes +

DSS specific information:

Scientific studies have shown a continuous relationship between lipid levels and coronary heart disease and overwhelming evidence that lipid lowering interventions reduce coronary heart disease progression, morbidity and mortality. Studies show a positive relationship between an individual's total blood cholesterol level and risk of coronary heart disease as well as death (Kannel & Gordon 1970; Pocock et al. 1989).

Many studies have demonstrated the significance of blood cholesterol components as risk factors for heart, stroke and vascular disease.

Several generalisations can be made from these cholesterol lowering trials:

  • that the results of the intervention trials are consistent with the prospective population studies in which (excluding possible regression dilution bias) a 1.0 mmol/L reduction in plasma total cholesterol translates into an approximate 20% reduction in the risk of future coronary events.
  • It should be emphasised, however, that this conclusion does not necessarily apply beyond the range of cholesterol levels which have been tested in these studies.
  • That the benefits of cholesterol lowering are apparent in people with and without coronary artery disease.

There is high level evidence that in patients with existing coronary heart disease, lipid intervention therapy reduces the risk of subsequent stroke


Cardiovascular disease (clinical) NBPDS Health, Standard 17/10/2018

DSS specific attributes +

DSS specific information:

Scientific studies have shown a continuous relationship between lipid levels and coronary heart disease and overwhelming evidence that lipid lowering interventions reduce coronary heart disease progression, morbidity and mortality. Studies show a positive relationship between an individual's total blood cholesterol level and risk of coronary heart disease as well as death (Kannel & Gordon 1970; Pocock et al. 1989).

Many studies have demonstrated the significance of blood cholesterol components as risk factors for heart, stroke and vascular disease.

Several generalisations can be made from these cholesterol lowering trials:

  • that the results of the intervention trials are consistent with the prospective population studies in which (excluding possible regression dilution bias) a 1.0 mmol/L reduction in plasma total cholesterol translates into an approximate 20% reduction in the risk of future coronary events.
  • It should be emphasised, however, that this conclusion does not necessarily apply beyond the range of cholesterol levels which have been tested in these studies.
  • That the benefits of cholesterol lowering are apparent in people with and without coronary artery disease.

There is high level evidence that in patients with existing coronary heart disease, lipid intervention therapy reduces the risk of subsequent stroke


Help
Downloading

The download may take a while, please wait.

Do not refresh the screen until the download is complete.

<Title>

<body>
<footer>
  • View
  • Show more
  • Print view
  • Download
  • Word™
  • Pdf
  • Advanced Download
  • Review
  • Compare items
© Australian Institute of Health and Welfare
Version 1.0.0+20220531.2